Phase I study of lenalidomide in acute leukemias and chronic lymphocytic leukemia.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia; Leukaemia
- Focus Adverse reactions
- 20 Oct 2014 Planned primary completion date changed from 1 Apr 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 20 Oct 2011 Celgene Corporation as trial company and lead trial centre added as reported by ClinicalTrials.gov.
- 20 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.